Gallium-68: Chemistry and radiolabeled peptides exploring different oncogenic pathways

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 2, 2013, Pages 85-97

  Morgat, Clement ^a   Hindie, Elif ^a   Mishra, Anil K ^a   Allard, Michèle ^a   Fernandez, Philippe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

68Ga; cancer; molecular imaging; PET; radiopharmaceuticals

Indexed keywords

1,4,7 TRIAZACYCLONONANE N,N'',N''' TRIACETIC ACID; 6 FLUORODOPA F 18; ACETIC ACID C 11; ACETIC ACID DERIVATIVE; BOMBESIN; CARBON 11; CASPASE 3; CHOLINE C 11; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GAMMA UROGASTRONE; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE; GONADORELIN; INTERMEDIN; MATRIX METALLOPROTEINASE; METHIONINE C 11; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTENSIN RECEPTOR; PENTETREOTIDE; PENTETREOTIDE IN 111; PROTEIN KINASE B; SOMATOSTATIN; TETRAXETAN; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 86;

APOPTOSIS; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHELATION; COMPLEX FORMATION; CYCLOTRON; DENATURATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RECEPTOR BINDING; ELECTRON CAPTURE DETECTION; GASTRINOMA; GENITAL TRACT CANCER; HALF LIFE TIME; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MITOSIS; MOLECULAR IMAGING; MOLECULAR WEIGHT; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS ADENOCARCINOMA; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOCHEMISTRY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GALLIUM RADIOISOTOPES; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84874695681     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1244     Document Type: Review

References (116)

1. Groheux D, Hindie E. Delord M, et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;12:12.
2. Taghilo M. Cyclotron production of 89Zr: A potent radionuclide for positron emission tomography. Int J the Phys Sci 2012;7:389.
3. Qaim SM. Decay data and production yields of some nonstandard positron emitters used in PET. Q J Nucl Med Mol Imaging 2008;52:111.
4. Monographie BIPM-5-Table of Radionuclides (Vol. 6- A= 22 to 242). Consultative Committee for Ionizing Radiation; 2011. Updated Last Updated Date.
5. Monographie BIPM-5-Table of Radionuclides (Vol. 1-A= 1 to 150). Consultative Committee for Ionizing Radiation; 2004. Updated Last Updated Date.
6. Gomzina NA, Kuznetsova OF. [L-[methyl-(11C)]-methionine of high enantiomeric purity production via on-line 11Cmethylation of L-homocysteine thiolactone hydrochloride]. Bioorg Khim 2011;37:216.
7. Shao X, Hockley BG, Hoareau R, et al. Fully automated preparation of [11C]choline and [18F]fluoromethylcholine using TracerLab synthesismodules and facilitated quality control using analytical HPLC. Appl Radiat Isot 2011;69:403.
8. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy- D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235.
9. Firnau G, Chirakal R, Garnett ES. Aromatic radiofluorination with [18F]Fluorine Gas: 6-[18F]-Fluoro-LDopa. J Nucl Med 1984;25:1228.
10. Wuest F. Aspects of positron emission tomography radiochemistry as relevant for food chemistry. Amino Acids 2005;29:323.
11. Schroeder RP, de Visser M, van Weerden WM, et al. Androgen- regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int J Cancer 2010;126:2826.
12. Wester HJ, Hamacher K, Stocklin G. A comparative study of N.C.A fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996; 23:365.
13. Pruszynski M, Loktionova NS, Filosofov DV, et al. Postelution processing of 44Ti/44Sc generator-derived 44Sc for clinical application. Appl Radiat Isot 2010;68:1636.
14. Fukumura T, Okada K, Suzuki H, et al. An improved 62Zn/62Cu generator based on a cation exchanger and its fully remote-controlled preparation for clinical use. Nucl Med Biol 2006;33:821.
15. Klein R, Adler A, Beanlands RS, et al. Precision-controlled elution of a 82 Sr/82 Rb generator for cardiac perfusion imaging with positron emission tomography. Phys Med Biol 2007;52:659.
16. Welch MJ, McCarthy TJ. The potential role of generatorproduced radiopharmaceuticals in clinical PET. J Nucl Med 2000;41:315.
17. Roesch F. Scandium-44: Benefits of a long-lived PET radionuclide available from the 44Ti/44Sc generator system. Curr Radiopharm 2012;5:187.
18. Alshoukr F, Prignon A, Brans L, et al. Novel DOTAneurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem 2011;22:1374.
19. Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669.
20. Autio A, Ujula T, Luoto P, et al. PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: Comparison with 18F-FDG. Eur J Nucl Med Mol Imaging 2010;37:1918.
21. Alonso O, Gambini JP, Lago G, et al. In vivo visualization of somatostatin receptor expression with Ga-68-DOTATATE PET/CT in advanced metastatic prostate cancer. Clin Nuclear Med 2011;36:1063.
22. Cagnolini A, Chen J, Ramos K, et al. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga- AMBA, and the synthesis and characterization of (nat)Ga- AMBA and [(67)Ga]Ga-AMBA. Appl Radiat Isot 2010; 68:2285.
23. Maschauer S, Einsiedel J, Hocke C, et al. Synthesis of a 68Ga-labeled peptoid-peptide hybrid for imaging of neurotensin receptor expression in vivo. ACS Med Chem Lett 2010;1:224.
24. Strauss LG, Koczan D, Seiz M, et al. Correlation of the Ga- 68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays. Mol Imaging Biol 2012;14:376.
25. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, et al. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: Comparison with 18F-FDG. J Nucl Med 2007;48:1245.
26. Eder M, Knackmuss S, Le Gall F, et al. 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging 2010;37:1397.
27. Reubi JC, Erchegyi J, Cescato R, et al. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. Eur J Nucl Med Mol Imaging 2010; 37:1551.
28. Wadas TJ, Wong EH, Weisman GR, et al. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010;110:2858.
29. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics 2011;1:30.
30. Mirzadeh S, Lambrecht RM. Radiochemistry of Germanium. J Radioanal Nucl Chem 1996;202:7.
31. Chakravarty R, Shukla R, Ram R, et al. Development of a nano-zirconia based 68Ge/68Ga generator for biomedical applications. Nucl Med Biol 2011;38:575.
32. Nakayama M, Haratake M, Ono M, et al. A new 68Ge/ 68Ga generator system using an organic polymer containing N-methylglucamine as adsorbent for 68Ge. Appl Radiat Isot 2003;58:9.
33. Bandoli G, Dolmella A, Tisato F, et al. Mononuclear sixcoordinated Ga(III) complexes: A comprehensive survey. Coord Chem Rev 2009;253:56.
34. Maecke HR, Hofmann M, Haberkorn U. 68Ga-Labeled peptides in Tumor Imaging. J Nucl Med 2005;46:172.
35. Reichert DE, Lewis JS, Anderson CJ. Metal complexes as diagnostic tools. Coord Chem Rev 1999;184:3.
36. Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. Biochemistry 1983;22:292.
37. Viola NA, Rarig RS, Ouellette W, et al. Synthesis, structure and thermal analysis of the gallium complex of 1,4,7,10- tetraazacyclo-dodecane- NN'N''N'''-tetraacetic acid (DOTA). Polyhedron 2006;25:3457.
38. Velikyan I, Maecke HR, La?ngstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem 2008;19:569.
39. Tanaka K, Fukase K. PET (positron emission tomography) imaging of biomolecules using metal-DOTA complexes: A new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics. Org Biomol Chem 2008;6:815.
40. Hancock RD. Chelate Ring Size and Metal Ion selection. J Chem Educ 1992;69:615.
41. Pruszynski M, Majkowska-Pilip A, Loktionova NS, et al. Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc. Appl Radiat Isot 2012;70:974.
42. van Essen M, Krenning EP, Kooij PP, et al. Effect of therapy with [177Lu-DOTA0,Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47:1599.
43. Valencak J, Heere-Ress E, Traub-Weidinger T, et al. Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: In-vitro and in-vivo results. Melanoma Res 2005;15:523.
44. Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486.
45. Wild D, Frischknecht M, Zhang H, et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res 2011;71:1009.
46. Cheng KT, Lewis JS, Biddlecombe GB. 86Y-DOTA-[Pro1,- Tyr4]-Bombesin[1-14] . Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Information; 2008.
47. Asti M, Tegoni M, Farioli D, et al. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: A perspective study for enhancing the 90Y and 177Lu labeling conditions. Nucl Med Biol 2012;39:509.
48. Beer AJ, Kessler H, Wester HJ, et al. PET Imaging of Integrin avb3 expression. Theranostics 2011;1:48.
49. Liu Z, Niu G, Shi J, et al. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: Promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 2009;36:947.
50. Knetsch PA, Petrik M, Griessinger CM, et al. [68Ga]NODAGA- RGD for imaging alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2011;38:1303.
51. Kaur A, Dasanu CA. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert Opin Pharmacother 2011;12:2493.
52. Tolmachev V, Velikyan I, Sandstrom M, et al. A HER2- binding Affibody molecule labelled with 68Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010; 37:1356.
53. Baum RP, Prasad V, Muller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 2010;51:892.
54. Speirs CK, Hwang M, Kim S, et al. Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res 2011;1:43.
55. Zhivotovsky B, Orrenius S. Calcium and cell death mechanisms: A perspective from the cell death community. Cell Calcium 2011;50:211.
56. Niu G, Chen X. Apoptosis imaging: Beyond annexin V. J Nucl Med 2010;51:1659.
57. Ungethum L, Kenis H, Nicolaes GA, et al. Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies. J Biol Chem 2011;286:1903.
58. Boersma HH, Kietselaer BL-JH, Stolk LML, et al. Past, present, and future of annexin A5: From protein discovery to clinical applications. J Nucl Med 2005;46:2035.
59. Bauwens M, De Saint-Hubert M, Devos E, et al. Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol 2011;38:381.
60. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008;19:52.
61. Ujula T, Huttunen M, Luoto P, et al. Matrix metalloproteinase 9 targeting peptides: Syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model. Bioconjug Chem 2010;21:1612.
62. Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase- 1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11:5158.
63. Guillermet-Guibert J, Lahlou H, Pyronnet S, et al. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: Molecular aspects. Best Pract Res Clin Gastroenterol 2005;19:535.
64. Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010;62:1005.
65. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2008;286:238.
66. Gabriel M, Decristoforo C, Kendler D, et al 68Ga-DOTATyr3- Octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508.
67. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617.
68. Ambrosini V, Nanni C, Zompatori M, et al. (68)Ga-DOTANOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:722.
69. Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35:1431.
70. Haug AR, Auernhammer CJ, Wangler B, et al. 68Ga- DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010;51:1349.
71. Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPAoctreotide scintigraphy. J Nucl Med 2010;51:875.
72. Poeppel TD, Binse I, Petersenn S. et al. Differential uptake of 68Ga-DOTATOC and 68Ga-DOTATAE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res 2013;194:353.
73. Jensen RT, Battey JF, Spindel ER, et al. International Union of Pharmacology. LXYIII. Mammalian Bombesin Receptors: Nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev 2008;60:1.
74. Gonzalez N, Moody TW, Igarashi H, et al. Bombesinrelated peptides and their receptors: Recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes 2008;15:58.
75. Beer M, Montani M, Gerhardt J, et al. Profiling gastrinreleasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate 2012;72: 318.
76. Flores DG, Meurer L, Uberti AF, et al. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull 2010;82:95.
77. Koopmans KP, Neels ON, Kema IP, et al. Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 2009; 71:199.
78. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49:318.
79. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single- photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009;15:5240.
80. Zhang H, Schuhmacher J, Waser B, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198.
81. Abiraj K, Mansi R, Tamma ML, et al. Bombesin antagonistbased radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011;52:1970.
82. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011;38:97.
83. Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369.
84. Evers BM. Neurotensin and growth of normal and neoplastic tissues. Peptides 2006;27:2424.
85. Alshoukr F, Rosant C, Maes V, et al. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor- positive tumors. Bioconjug Chem 2009;20:1602.
86. Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools. Peptides 2006;27:2445.
87. Korner M, Reubi JC. NPY receptors in human cancer: A review of current knowledge. Peptides 2007;28:419.
88. Kitlinska J. Neuropeptide Y in neural crest-derived tumors: Effect on growth and vascularization. Cancer Lett 2007; 245:293.
89. Ruscica M, Dozio E, Motta M, et al. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides 2007;28:426.
90. Korner M, Waser B, Reubi JC. Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. Int J Cancer 2005;115:734.
91. Medeiros PJ, Al-Khazraji BK, Novielli NM, et al. Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line. Int J Cancer 2012;131:276.
92. Kitlinska J. Neuropeptide Y (NPY) in neuroblastoma: Effect on growth and vascularization. Peptides 2007; 28:405.
93. Lu C, Everhart L, Tilan J, et al. Neuropeptide Y and its Y2 receptor: Potential targets in neuroblastoma therapy. Oncogene 2010;29:5630.
94. Zhang L, Bijker MS, Herzog H. The neuropeptide Y system: Pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 2011;131:91.
95. Korner M, Christ E, Wild D, Reubi JC. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol 2012;3.
96. Brom M, Oyen WJ, Joosten L, et al. 68Ga-labelled exendin- 3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010;37:1345.
97. Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide- 1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011; 52:1073.
98. Bohm M, Luger TA, Tobin DJ, et al. Melanocortin receptor ligands: New horizons for skin biology and clinical dermatology. J Invest Dermatol 2006;126:1966.
99. Eves PC, MacNeil S, Haycock JW. alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006;27:444.
100. Miao Y, Quinn TP. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 2008;67:213.
101. Wei L, Zhang X, Gallazzi F, et al. Melanoma imaging using (111)In-, (86)Y-and (68)Ga-labeled CHX-A-Re(Arg11)CCMSH. Nucl Med Biol 2009;36:345.
102. Liu SV, Schally AV, Hawes D, et al. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res 2010;16:4675.
103. Millar RP, Pawson AJ, Morgan K, et al. Diversity of actions of GnRHs mediated by ligand-induced selective signaling. Front Neuroendocrinol 2008;29:17.
104. Harrison GS, Wierman ME, Nett TM, et al. Gonadotropinreleasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer 2004;11:725.
105. Hapgood JP, Sadie H, van Biljon W, et al. Regulation of expression of mammalian gonadotrophin-releasing hormone receptor genes. J Neuroendocrinol 2005;17:619.
106. Schottelius M, Berger S, Poethko T, et al. Development of novel 68Ga-and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconjug Chem 2008; 19:1256.
107. Gourni E, Demmer O, Schottelius M, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 2011;52:1803.
108. Brom M, Joosten L, Laverman P, et al. Preclinical evaluation of 68Ga DOTA minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors. Mol Imaging 2011;10:144.
109. Thews O, Dillenburg W, Fellner M, et al. Activation of Pglycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: In vivo imaging with 68Ga-labelled PET tracer. Eur J Nucl Med Mol Imaging 2010;37:1935.
110. Hoigebazar L, Jeong JM, Choi SY, et al. Synthesis and characterization of nitroimidazole derivatives for 68Galabeling and testing in tumor xenografted mice. J Med Chem 2010;53:6378.
111. Fani M, Wang X, Nicolas G, et al. Development of new folate-based PET radiotracers: Preclinical evaluation of 68Ga-DOTA-folate conjugates. Eur J Nucl Med Mol Imaging 2011;38:108.
112. Fellner M, Baum RP, Kubicek V, et al. PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: First human study. Eur J Nucl Med Mol Imaging 2010; 37:834.
113. Burchardt C, Riss PJ, Zoller F, et al. [(68)Ga]Ga-DO(2)A-(OBul- tyr)(2): Synthesis, (68)Ga-radiolabeling and in vitro studies of a novel (68)Ga-DO(2)A-tyrosine conjugate as potential tumor tracer for PET. Bioorg Med Chem Lett 2009;19:3498.
114. Roivainen A, Tolvanen T, Salomaki S, et al. 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med 2004;45:347.
115. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: Initial experiences and comparison to PET/CT. J Nucl Med 2010;51:1198.
116. Pichler BJ, Wehrl HF, Kolb A, et al. Positron emission tomography/magnetic resonance imaging: The next generation of multimodality imaging? Semin Nucl Med 2008; 38:199.